← Leaderboards
Andrew L Salzman
Inotek Pharmaceuticals Corporation
$19,918,828
Attributed
$19,918,828
Total exposure
21
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$19,918,828 · 21
By mechanism
R44$17,047,636 · 11
R43$1,995,628 · 8
R01$875,564 · 2
Top collaborators
No co-investigators on record.
Most similar at Inotek Pharmaceuticals Corporation
Same institution · by research overlap
- Prakash Jagtap$6,029,479
- Garry John Southan$13,828,224
- Kanneganti Murthy$5,565,701
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationPharmacokineticsClinical ResearchNitric OxideEnzyme InhibitorsDoseClinical TrialsDrug Design /Synthesis /ProductionLaboratory RatCytokineAnimal ModelClinically RelevantNitric Oxide SynthasePentosyltransferaseAntiinflammatory AgentsCatalystInflammationMedicalInnovationLaboratory MouseDrug Adverse EffectInjuryAcuteFree Radicals
Grant awards (29)
Restoration of free radical homeostasis: novel therapy of septic shock$1,194,948
R44 · FY2017 · GM · contact PI
Restoration of free radical homeostasis: novel therapy of septic shock$1,248,631
R44 · FY2016 · GM · contact PI
Treatment of congenital heart disease associated pulmonary hypertension$1,500,000
R44 · FY2015 · HD · contact PI
A potassium-ATP channel opener for prevention of contrast-induced nephropathy$1,527,261
R44 · FY2014 · DK · contact PI
A Novel Immunotolerizing Therapy for Autoimmune Vitiligo$225,000
R43 · FY2014 · AR · contact PI
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion$2,163,046
R44 · FY2013 · HL · contact PI
A Redox-active PARP Inhibitor for Lung Transplantation$390,713
R43 · FY2012 · HL · contact PI
Resuscitation of smoke inhalation and burn injury with a thioredoxin mimetic$291,523
R43 · FY2012 · HL · contact PI
A nitric oxide synthase inhibitor for uveitis$875,487
R44 · FY2007 · EY · contact PI
A nitric oxide synthase inhibitor for uveitis$1,222,967
R44 · FY2005 · EY
PARP inhibition for thoraco-abdominal aneurysm surgery$191,048
R43 · FY2005 · HL
Inosine pro-drug: novel therapy for arthritis$1,396,706
R44 · FY2004 · AR
PARP inhibitory therapy of acute ischemic stroke$434,230
R43 · FY2004 · NS
PARP inhibitor therapy for septic shock$210,226
R43 · FY2004 · GM
PARS inhibitor therapy for smoke inhalation$1
R44 · FY2004 · HL
PARS inhibitor therapy for smoke inhalation$1,271,724
R44 · FY2003 · HL
Peroxynitrite decomposition catalyst for bowel disease$640,351
R44 · FY2003 · DK
PARP inhibitor therapy for acute myocardial infarction$358,138
R44 · FY2003 · HL
Inosine pro-drug: novel therapy for arthritis$212,416
R44 · FY2003 · AR
Peroxynitrite decomposition catalyst for bowel disease$1,152,230
R44 · FY2002 · DK
REGULATION OF NITRIC OXIDE IN HUMAN ENTEROCYTES$232,310
R01 · FY2002 · GM
XO INHIBITOR FOR THERAPY OF ACETAMINOPHEN INTOXICATION$648,904
R44 · FY2001 · GM
REGULATION OF NITRIC OXIDE IN HUMAN ENTEROCYTES$225,585
R01 · FY2001 · GM
PARASITE-DERIVED INHIBITORS OF LEUKOCYTIC OXIDANT BURST$144,831
R43 · FY2001 · DK
CBC-NO: SELECTIVE PULMONARY VASODILATOR FOR SEPSIS$1,006,442
R44 · FY2000 · GM
XO INHIBITOR FOR THERAPY OF ACETAMINOPHEN INTOXICATION$628,384
R44 · FY2000 · GM
REGULATION OF NITRIC OXIDE IN HUMAN ENTEROCYTES$219,056
R01 · FY2000 · GM
POLY (ADP-RIBOSE) SYNTHETASE IN SPLANCHNIC I-R INJURY$198,613
R01 · FY2000 · GM
ADENOSINE 3 RECEPTOR AGONIST FOR TREATMENT OF COLITIS$108,057
R43 · FY2000 · DK